But we have concrete in the ground and superstructures going up on new pharmaceutical facilities in North Carolina, in Southern California and Indiana, in Georgia, and fill and finish facilities, new R and D Across the board. So that is a hugely positive development. We have them coming in companies from Switzerland, companies from Denmark, companies from France, companies from Japan. So we're seeing that happen, which is really, really encouraging. The generics, I agree with you, is a more challenging issue. (29:30–29:37)
CLAIM
Asserts that companies from Switzerland, Denmark, France, and Japan are investing in U.S. pharmaceutical facilities.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
